Moderna Postive News for mRNA-1273 Vaccine Against Novel Coronavirus (COVID-19)
Moderna (MRNA) announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2 or COVID-19), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID) which is part of the National Institutes of Health (NIH).
According to the firm’s press release, Immunogenicity data are currently available for the 25 µg and 100 µg dose level (ages 18-55) after two doses (day 43) and at the 250 µg level (ages 18-55) after one dose (day 29). Dose-dependent increases in immunogenicity were seen across the three dose levels and between prime and boost within the 25 µg and 100 µg dose levels. All participants ages 18-55 across all three dose levels seroconverted by day 15 after a single dose.